Psoriasis Vulgaris Clinical Trial
Official title:
Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules
In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%), 50 cases invalid(36.2%), 13 cases serious(9.4%). To investigate the influence of genetic factors on the curative effect and find the relationships between genetic variants and the response of Acitretin Capsules to treatment of Psoriasis Vulgaris.
Investigators analyzed the various levels of genetic factors, including: 1.To analysis the key gene variants which associated with ADME affect the efficacy of Acitretin Capsules; 2.Direct full genetic sequencing of MHC genes, to explore the genetic variations of efficacy and side effects; 3. Direct sequencing of all exons in the gene in the patients of the response of serious and effectively, to explores the rare genetic variation may cause deterioration of treatment by Acitretin Capsules. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03669757 -
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
|
Phase 1 | |
| Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT03584360 -
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
|
Phase 2 | |
| Recruiting |
NCT04994951 -
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
|
Phase 2 | |
| Completed |
NCT02888236 -
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
|
Phase 2 | |
| Completed |
NCT02533973 -
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
|
Phase 4 | |
| Completed |
NCT02193815 -
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
|
Phase 1 | |
| Completed |
NCT02004847 -
Blue Light for Treating Psoriasis Vulgaris
|
N/A | |
| Completed |
NCT01946386 -
A Vasoconstriction Study With LEO 90100
|
Phase 1 | |
| Recruiting |
NCT01443338 -
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
|
Phase 4 | |
| Completed |
NCT01188928 -
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
|
Phase 3 | |
| Completed |
NCT00764751 -
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
|
Phase 2 | |
| Completed |
NCT00236171 -
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
|
N/A | |
| Completed |
NCT04541329 -
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
|
Phase 4 | |
| Completed |
NCT06064084 -
Incretin Effect in Patients With Psoriasis and Controls
|
||
| Not yet recruiting |
NCT06398106 -
Proactive TDM Versus Standard Use of Biologics in Psoriasis
|
Phase 4 | |
| Recruiting |
NCT05892640 -
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
|
N/A | |
| Recruiting |
NCT05390515 -
Psoriatic Immune Response to Tildrakizumab
|
Phase 4 | |
| Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
| Completed |
NCT05184348 -
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
|
Phase 1 |